A team of scientists found therapeutic treatment using radiopharmaceutical I-131 mIBG can effectively mitigate symptoms of certain neuroendocrine tumors and resulted in improved prognosis for patients with symptomatic progression, radiographic response or stability and biochemical response.
A new discovery involving diamonds may significantly cut costs related to medical imaging and drug-discovery devices, according to a team of researchers led by the U.S. Department of Energy and the University of California, Berkeley.
A team of German researchers used PET/CT and modeling practices to create a new method to pattern and predict tumor response in radioligand therapy (RLT), which authors say is the first attempt to do so.
The "disease screening pill," developed by researchers from the University of Michigan, lit up malignant tumors in mice when exposed to near-infrared light—all without the use of radiation, according to a study published in Molecular Pharmaceutics.
On May 17, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the Value Initiative Industry Alliance—a collaboration among corporate community members that will help implement the organization’s Value Initiative and advance nuclear medicine.
A prospective comparison study of two PET tracers found 18F-FDG could provide valuable measures of activity in bone-dominant (BD) metastatic breast cancer (MBC) patients, while also predicting responses to therapy.
The National Institutes of Health (NIH) announced efforts to widen the scientific community's access to cryo-electron microscopy (cryo-EM) through its Transformative High Resolution Cryo-Electron Microscopy program.
A team at the University of Alberta in Canada has devised a method utilizing a cyclotron particle accelerator to produce the radioactive tracer technetium-99m—the parent of Molybdenum-99. It may be able to produce enough radioactive isotope for the entire province, CBC.ca reports.
Scientists at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) announced they had merged two microscope technologies to generate clearer images of rapid processes occurring inside human cells.
A team of Johns Hopkins University researchers—conducting the first in-human PET study of three novel tau radiopharmaceuticals in Alzheimer’s disease patients—found [18F]RO-948 was the most capable for characterizing tau pathology in the disease.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) addressed two letters to Aetna recommending the health insurance giant alter its radiopharmaceutical coverage policy to include PET imaging agents dotatate and fluciclovine.
A high-tech microscope developed by scientists at the University of Virginia (UVA) School of Medicine has captured images of cancer-causing viruses clinging to human DNA, according to a UVA Health System release.